{"id":45018,"date":"2024-12-16T14:22:03","date_gmt":"2024-12-16T13:22:03","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=45018"},"modified":"2024-12-16T14:22:05","modified_gmt":"2024-12-16T13:22:05","slug":"2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/","title":{"rendered":"2019’s stock darling rise 166% and Expres2ion announce positive phase IIb data for malaria vaccine"},"content":{"rendered":"\n

NORDIC | BIOTECH & HEALTHCARE<\/strong> Your insights into listed Danish & Nordic biotech & healthcare stocks.<\/em><\/p>\n\n\n\n

In the past week, the Nordic biotech and healthcare stocks increased by 0.7%. Expres2ion announced encouraging phase IIb data for a blood-stage malaria vaccine, FDA accepted supplemental BLA for TransCon, Evaxion Biotech announced proof-of-concept in AI vaccine, and 12.7% of Curasight’s warrants of series TO2 were subscribed. Furthermore, a Nordic stock darling from 2019 suddenly rose 166%. <\/strong> <\/p>\n\n\n\n

On average, Danish biotech and healthcare stocks delivered a negative return of 1%. ExpreS2ion<\/a><\/strong> rose 15% following positive phase IIb data for a blood-stage malaria vaccine. FDA also accepted Ascendis Pharma<\/a><\/strong>‘s Supplemental Biologics License Application for TransCon. Further, Evaxion Biotech<\/a><\/strong> declined 18% after they announced proof-of-concept for a new cancer vaccine concept. The stock is currently in a downward trend, down 62% in the past 3 months, and last week’s negative return is most likely only a result of that. Finally, the subscription of Curasight<\/a><\/strong>‘s TO2 warrants was only 12.7% generating MDKK 5.4 before costs.<\/p>\n\n\n\n

7 of the 22 Danish biotech companies had a positive share price development in the past week and 12 companies have had a positive share price performance year-to-date. Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong YTD performance.<\/strong> 5 <\/strong><\/span>Danish healthcare stocks with +100% YTD return.<\/strong><\/p>\n\n\n\n

\n
Register for the Nordic I Impact newsletter here.<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Danish company news<\/strong><\/p>\n\n\n\n

Acarix AB<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Ascendis Pharma<\/a><\/strong><\/p>\n\n\n\n

FDA Accepts Ascendis Pharma\u2019s Supplemental Biologics License Application for TransCon\u2122 hGH for the Treatment of Adults with Growth Hormone Deficiency<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Biosergen<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Cessatech<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

CS Medica<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Curasight<\/a><\/strong><\/p>\n\n\n\n

Curasight A\/S announces outcome of warrant exercise (Link<\/a>)<\/p>\n\n\n\n

Participation in warrant exercise by Curasight management (Link<\/a>)<\/p>\n\n\n\n

DanCann Pharma<\/a><\/strong><\/p>\n\n\n\n

DanCann Pharma Announces Outcome of Directed Issues to Board and Management<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Evaxion Biotech<\/a><\/strong><\/p>\n\n\n\n

Evaxion announces 2025 milestones reflecting continued strong strategy execution<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Evaxion establishes new AI-derived precision cancer vaccine concept (Link<\/a>)<\/p>\n\n\n\n

ExpreS2ion<\/a><\/strong><\/p>\n\n\n\n

Publication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine (Link<\/a>)<\/p>\n\n\n\n

Fluoguide<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Genmab<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Gubra<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Initiator Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

IO Biotech<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Pila Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Saniona<\/a><\/strong><\/p>\n\n\n\n

Saniona repays the remaining debt and converts convertibles to Fenja Capital II A\/S<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Scandion Oncology<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

SynAct Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

ViroGates<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Zealand Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Y-mAbs Therapeutic<\/a><\/strong><\/p>\n\n\n\n

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

2cureX<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em>k<\/p>\n\n\n\n

Share price development \u2013 Danish stocks<\/strong><\/p>\n\n\n\n

On average, Danish biotech and healthcare stocks delivered a negative return of 1%. ExpreS2ion<\/a><\/strong> rose 15% following positive phase IIb data for a blood-stage malaria vaccine. FDA also accepted Ascendis Pharma<\/a><\/strong>‘s Supplemental Biologics License Application for TransCon. Further, Evaxion Biotech<\/a><\/strong> declined 18% after they announced proof-of-concept for a new cancer vaccine concept. The stock is currently in a downward trend with a decline of 62% in the past 3 months, and last week’s negative return is most likely a result of week trading than because of the news. Finally, the subscription of Curasight<\/a><\/strong>‘s TO2 warrants was only 12.7% generating MDKK 5.4 before costs.<\/p>\n\n\n\n

Gubra<\/a><\/strong> continues to be the best-performing stock year-to-date with a return of 452%. Pila Pharma<\/a>, Saniona<\/a><\/strong>, Zealand Pharma<\/a><\/strong> and ViroGates<\/a><\/strong> have also generated more than a 100% return. <\/p>\n\n\n\n

Investment case for Curasight<\/a><\/strong><\/p>\n\n\n\n

Overview of share price development the past week, year-to-date, and the last twelve month<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Nordic Biotech & Healthcare Developments<\/mark><\/strong><\/p>\n\n\n\n

The <\/span>Kapital Partner Nordic Healthcare Index (KPHC) increased by 0.7% to 64,45 in the past week. After a good start to the year, the index declined together with the other indexes from July to November, and now the indexes seem to be running upwards again. The 1-year return for the KPHC index has almost been erased by the past months of poor performance from August to November.<\/p>\n\n\n\n

The Nordic healthcare stocks (KPHC) vs. C25, S30, and KPNGX the past year<\/strong><\/p>\n\n\n\n

\"\"
The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.<\/sup><\/figcaption><\/figure>\n\n\n\n

The top three best-performing stocks in the past week<\/strong><\/p>\n\n\n\n

Spectracure AB<\/a><\/strong> (166%)<\/strong> specializes in the research and development of medical technology systems used to treat prostate cancer. The cancer treatments are based on proprietary systems that emit laser light sources and photoreactive drugs, a treatment methodology used for internal solid tumors of various types. The company signed a contract with an American hospital regarding a clinical study for prostate cancer. In 2019, the stock was one of the best-performing stocks in the Nordics, with very high trading volumes.<\/p>\n\n\n\n

PharmaLundensis AB <\/a>(115%)<\/strong> main focus is in the treatment of severe lung diseases. Diseases in which the company specializes include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition to its core business, the company develops technical systems for drug release management. The company got a positive patent update on Phal-501 during the week.<\/p>\n\n\n\n

WntResearch AB<\/a><\/strong> (35%)<\/strong> is a biotechnology company developing a therapy to counteract cancer metastasis. The company’s research is focused on studies of the endogenous protein WNT5A, which has been shown in studies to affect the ability of tumour cells to move and spread. The company’s drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is being evaluated in the NeoFox phase 2 clinical trial in patients with stage II-III colon cancer, however with non-perfoming results. In the past week, the CEO’s contract was terminated.<\/p>\n\n\n\n

Resources: Refinitiv Eikon, Cision, Nordnet & company websites<\/strong><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks increased by 0.7%. Expres2ion announced encouraging phase IIb data for a blood-stage malaria vaccine, FDA accepted supplemental BLA for TransCon, Evaxion Biotech announced proof-of-concept in AI vaccine, and 12.7% of […]<\/p>\n","protected":false},"author":2,"featured_media":43132,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[9,29,165],"tags":[],"class_list":["post-45018","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-en-investeringscases","category-investeringscases","category-investment-cases"],"acf":[],"yoast_head":"\n2019's stock darling rise 166% and Expres2ion announce positive phase IIb data for malaria vaccine | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2019's stock darling rise 166% and Expres2ion announce positive phase IIb data for malaria vaccine | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks increased by 0.7%. Expres2ion announced encouraging phase IIb data for a blood-stage malaria vaccine, FDA accepted supplemental BLA for TransCon, Evaxion Biotech announced proof-of-concept in AI vaccine, and 12.7% of […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-16T13:22:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-16T13:22:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"724\" \/>\n\t<meta property=\"og:image:height\" content=\"418\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kapital Partner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kapital Partner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/\"},\"author\":{\"name\":\"Kapital Partner\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/f79e57d92a60bb503a02eff0aadbe1fe\"},\"headline\":\"2019’s stock darling rise 166% and Expres2ion announce positive phase IIb data for malaria vaccine\",\"datePublished\":\"2024-12-16T13:22:03+00:00\",\"dateModified\":\"2024-12-16T13:22:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/\"},\"wordCount\":966,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"articleSection\":[\"All investment Cases\",\"Investeringscases\",\"Investment cases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/\",\"name\":\"2019's stock darling rise 166% and Expres2ion announce positive phase IIb data for malaria vaccine | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"datePublished\":\"2024-12-16T13:22:03+00:00\",\"dateModified\":\"2024-12-16T13:22:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"width\":724,\"height\":418},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investment cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"2019’s stock darling rise 166% and Expres2ion announce positive phase IIb data for malaria vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/f79e57d92a60bb503a02eff0aadbe1fe\",\"name\":\"Kapital Partner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0ac4318887c096ae923f37487d5e98fd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0ac4318887c096ae923f37487d5e98fd?s=96&d=mm&r=g\",\"caption\":\"Kapital Partner\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2019's stock darling rise 166% and Expres2ion announce positive phase IIb data for malaria vaccine | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/","og_locale":"en_US","og_type":"article","og_title":"2019's stock darling rise 166% and Expres2ion announce positive phase IIb data for malaria vaccine | Kapital Partner A\/S","og_description":"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks increased by 0.7%. Expres2ion announced encouraging phase IIb data for a blood-stage malaria vaccine, FDA accepted supplemental BLA for TransCon, Evaxion Biotech announced proof-of-concept in AI vaccine, and 12.7% of […]","og_url":"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2024-12-16T13:22:03+00:00","article_modified_time":"2024-12-16T13:22:05+00:00","og_image":[{"width":724,"height":418,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","type":"image\/jpeg"}],"author":"Kapital Partner","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Kapital Partner","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/"},"author":{"name":"Kapital Partner","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/f79e57d92a60bb503a02eff0aadbe1fe"},"headline":"2019’s stock darling rise 166% and Expres2ion announce positive phase IIb data for malaria vaccine","datePublished":"2024-12-16T13:22:03+00:00","dateModified":"2024-12-16T13:22:05+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/"},"wordCount":966,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","articleSection":["All investment Cases","Investeringscases","Investment cases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/","url":"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/","name":"2019's stock darling rise 166% and Expres2ion announce positive phase IIb data for malaria vaccine | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","datePublished":"2024-12-16T13:22:03+00:00","dateModified":"2024-12-16T13:22:05+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","width":724,"height":418},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/2019s-stock-darling-rise-166-and-expres2ion-announce-positive-phase-iib-data-for-malaria-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Investment cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/"},{"@type":"ListItem","position":3,"name":"2019’s stock darling rise 166% and Expres2ion announce positive phase IIb data for malaria vaccine"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/f79e57d92a60bb503a02eff0aadbe1fe","name":"Kapital Partner","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0ac4318887c096ae923f37487d5e98fd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ac4318887c096ae923f37487d5e98fd?s=96&d=mm&r=g","caption":"Kapital Partner"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/45018"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=45018"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/45018\/revisions"}],"predecessor-version":[{"id":45019,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/45018\/revisions\/45019"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/43132"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=45018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=45018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=45018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}